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Abstract
Introduction: The raw incidence of cancer of the uterine cervix is Spain is 7,8 per 100.000
inhabitants (adjusted incidence is 5.6). The incidence of this tumor is still low, but a steady increase
has been seen, probably related to increasing risk factors.
Aim: To determine the frequency of infection by different types of human papillomavirus (HPV) in
Papanicolau smears from women with and without cancer of the uterine cervix in Spain.
Patients and methods: A case-control study was performed in women with and without cervical
cancer from Zaragoza, Spain. Pap smears from 600 cases (540 women with cervical intraepithelial
neoplasms (CIN) and 60 with invasive cancer) and 1200 controls (women without those lesions)
were tested by polymerase chain reaction (PCR) and typed by oligonucleotide microarray-based
detection.
Results: HPV was detected in 93.3% of all samples with invasive cancer versus 17.5% of controls.
OR for invasive cancer was 55 (95% CI 21.5–140,5). Statistically significant associations were also
found for different grades of cervical dysplasia.
Conclusion: The strong association found between HPV infection, specifically types 16 and 18 and
cancer of the uterine cervix in Zaragoza, Spain, stresses the importance of ongoing efforts to
institute a vaccine program with recently approved HPV vaccines in order to prevent cervical
cancer in this population.
Background
Cancer of the uterine cervix is more frequent in develop-
ing countries than in the Western world. Spain, a country
where screening through Papanicolau smears has been
performed for more than 30 years now, has a low raw inci-
dence of 7.8 in 2000 (age-adjusted rate is 5.6) [1].
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In the last decade, an increasing incidence of cervical can-
cer has been noted, most likely related to increasing num-
bers of young women with risk factors, namely sexual
promiscuity and prostitution.
The fact that these high-risk women, some of whom are
foreign immigrants, are not adhering to screening pro-
grams, stresses the importance of developing alternative
strategies for prevention.
While there are many genotypes of human papillomavi-
rus and most of them are frequently found in Pap smears
of healthy women, two genotypes, 16 and 18, of human
papillomavirus have been consistently associated to
intraepithelial neoplasia and invasive cancer of the uter-
ine cervix in Western populations [2] and have been
included in papillomavirus vaccines. However, it must be
noted that additional genotypes that are not included in
the first generation of human papillomavirus vaccines,
that has just been approved for clinical use, are frequently
associated to intraepithelial and invasive cervical neopla-
sia in South America and Asia.
We have performed a case-control study to assess the inci-
dence of infection by different HPV types in women with
and without cervical dysplasia and carcinoma. Following
PCR-based detection of HPV, oligonucleotide microarray-
based detection was used for genotyping, given its reliabil-
ity and ease of use.
Methods
Following approval by the Institutional review Board of
the University of Zaragoza, the study included six hun-
dred consecutive women with some degree of cervical dys-
plasia or neoplasia (CIN I, CIN II, CIN III and invasive
cancer) excluding atypical squamous cells of uncertain
significance (ASCUS) who had Pap smears at the Univer-
sity Hospital of Zaragoza, Spain from 1999 to 2005. Cyto-
logical diagnoses were required to have been
subsequently confirmed by histology for study entry.
Controls were 1200 age-matched women who had no cer-
vical dysplasia, neoplasia or ASCUS in the Pap smear, for
a case:control ratio of 1:2.
In addition to standard cytologic examination, all Pap
smears from cases and controls underwent DNA extrac-
tion and were tested for HPV by polymerase chain reac-
tion (PCR) and typed by oligonucleotide microarray-
based detection [3] with positive and negative controls.
Statistical analysis included a logistic regression analysis
adjusted for age, calculating odds ratio (OR) for each type
of cervical lesion (CIN I, CIN II; CIN III and invasive can-
cer) and 95% confidence intervals in women with and
without HPV positivity in the Pap smear.
Results
The study population included 1800 women. Median age
was 36 years. There were 3.3% foreign-born individuals.
The number of samples in each diagnostic group was: 120
patients (20%) with CIN I, 210 (35%) with CIN II, 210
(35%) with CIN III and 60 (10%) with invasive cervical
carcinoma. All these cytological diagnoses had been sub-
sequently confirmed by histology. The frequency of HPV
positivity according to type of cervical lesion is shown in
Table 1. Overall, 79% of cases and 17% of controls tested
positive for HPV. According to the type of lesion, 66% of
patients with CIN I tested positive for HPV, as did 71% of
those with CIN II, 90% of those with CIN III and 90% of
patients with invasive cervical carcinoma.
As for HPV types (Table 2), the most frequent type of HPV
found in women with CIN I, CIN II, CIN III and invasive
carcinoma was HPV-16, followed by HPV-18. In patients
with CIN, these two genotypes comprised 55% of HPV
infections detected, versus 80% in patients with CIN II
and 90% in patients with CIN III. In patients with invasive
carcinoma, HPV-16 and HPV-18 comprised 98% of all
HPV infections detected.
It is remarkable that HPV 16 and HPV 18 were infrequent
among controls, comprising only 1% of all HPV infec-
tions.
Table 3 shows the odds ratio for each type of cervical
lesion in women with or without HPV positivity. The odds
ratio was higher for high-grade lesions, ranging from 6 for
CIN I to 55 for infiltrating carcinoma.
Discussion
In the present study, the correlation between HPV and cer-
vical neoplasia has been different for early lesions (odds
ratio for CIN I = 6; odds ratio for CIN II = 10) than for
higher-risk lesions (odds ratio for CIN III = 16; odds ratio
for invasive carcinoma = 55).
Table 1: Frequency of HPV positivity according to type of 
cervical lesion found in Pap smears.
Pathological diagnosis Number of patients Number (%) HPV +
CIN I 120 80 (66%)
CIN II 210 150 (71%)
CIN III 210 190 (90%)
Invasive carcinoma 60 56 (93%)
Total cases 600 476 (79%)
Controls 1200 210 (17%)Infectious Agents and Cancer 2008, 3:8 http://www.infectagentscancer.com/content/3/1/8
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Overall, the odds ratio found in our study is well within
values reported in prior articles, ranging from a lowest
value of 2 (95% confidence interval = 1.5–2.6) in a series
of women with cancer of the uterine cervix from the
United Kingdom to a high odds ratio of 813 (95% confi-
dence interval = 168–3229) seen in another study [4].
Other authors found intermediate values, such as 18.5
(95% confidence interval = 5.9–57.6) [5] and 67.2 (95%
confidence interval = 28.6–157.5) [6]. The odds ratio in
women with HPV and coexisting HIV infection was found
to be 16.8 (95% confidence interval = 7.0–40.3) [7].
Such large differences in studies that are otherwise con-
cordant in showing a significant association between HPV
infection and cervical cancer may well be due to differ-
ences in the type of pathological lesion, the viral load and
the duration of infection.
In a study from Mexico [8], the odds ratio for CIN I in
women with low viral load was 16.8 (95% confidence
interval = 7.2–39), while the odds ratio for CIN II and CIN
III in women with high viral load was 365 (95% confi-
dence interval = 94.7–1412).
In the present study, a higher odds ratio was found for
more severe cervical lesions, reaching a maximum of 55
for invasive carcinoma, a figure that is remarkably similar
to that found in prior studies.
The fact that HPV detection was performed just after cyto-
logical examination, without the long storing periods
seen in some prior studies [9] supports the reliability of
the present data.
Both HPV-16 and HPV-18 were significantly more fre-
quent in cases than in controls, as seen in prior reports
[10-15]. There is a trend to increasing percentage of HPV-
16 and HPV-18 infections in patients with CIN III (90%)
as compared to those with CIN I (55%).
An interesting finding in our study is the high prevalence
of HPV-54 in controls (12%) and patients with CIN I
(27%). The fact that the prevalence of HPV-54 in patients
with CIN III and invasive carcinoma was much lower (0%
and 2%) suggests that this type has a low potential to
induce invasive cancer.
Prior studies have found other HPV genotypes different
from HPV-16 and HPV-18 to be related to cervical cancer
in specific geographic areas [16]. That is the case for HPV-
58, found frequently in women with cervical cancer in
Central and Soutth America [17] and China. This suggests
that the distribution of HPV types in women with squa-
mous cell carcinoma is heterogeneous around the world.
As in other studies performed in Spain [18], HPV 16 and
18 are the only genotypes that are significantly associated
to intraepithelial and invasive carcinoma of the uterine
cervix. It is possible that significant immigration from
South America and Asia might result in the appearance of
additional oncogenic genotypes not included in current
HPV vaccines.
It is remarkable that a significant percentage of healthy
women (controls) harbour HPV (17% in the present
study, similar to prior reports), even if the types were dif-
ferent from women with cervical lesions and the preva-
lence of types associated with cancer (namely HPV-16 and
HPV-18) was very low.
Table 2: Most frequent HPV genotypes found in the study according to the type of cervical lesion.
Pathological diagnosis
Genotype found CIN I CIN II CIN III Invasive carcinoma No cancer (control)
HPV-16 30% 30% 80% 90% 1%
HPV-18 25% 50% 10% 8% 0
HPV-1 10% 5% 0% 0% 30%
HPV-4 0% 3% 2% 0% 12%
HPV-31 7% 6% 3% 0% 49%
HPV-54 27% 4% 2% 0% 12%
Others 1% 2% 3% 2% 26%
Table 3: Odds ratio for each type of cervical lesion according to 
HPV status.
Type of lesion Odds ratio 95% Confidence interval
CIN I 6.0 3.7–9.7
CIN II 10.6 7.2–15.6
CIN III 16.7 10.5–26.4
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The high frequency of HPV found in controls suggests that
most were transient infections. Only women infected with
high-risk HPV types and with ineffective immune
response would develop neoplasia [19-21].
The distribution of HPV types associated to cervical cancer
in each area of the world needs to be taken into account
when designing HPV vaccines. This is an exciting time for
prevention of cancer of the uterine cervix, when two HPV
vaccines have already been proven to be effective in pre-
venting cervical cancer, and may soon improve public
health strategies against this disease, currently based
solely on early detection by Pap smears.
Conclusion
The strong association found in this report between HPV
infection, specifically types 16 and 18 and cancer of the
uterine cervix in Zaragoza, Spain, stresses the importance
of ongoing efforts to institute a vaccine program with two
recently approved HPV vaccines in order to prevent cervi-
cal cancer in this population.
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